Skip to content
Evigrade
MinorDirect oral anticoagulants (factor Xa inhibitors)×Proton pump inhibitors

Updated · Methodology

Mechanism

Apixaban has multiple elimination routes. It is metabolised mainly by CYP3A4/5, with minor contributions from CYP1A2, CYP2C8, CYP2C9, CYP2C19 and CYP2J2. Renal excretion accounts for about 27% of total clearance, and much of the dose is eliminated in faeces (apixaban SmPC, European Medicines Agency, EMA, section 5.2). Reducing gastric acidity does not affect apixaban: famotidine 40 mg changed neither apixaban AUC nor Cmax. Apixaban inhibits CYP2C19 only at concentrations far above those seen in patients (apixaban SmPC, EMA, section 4.5). Omeprazole is completely metabolised by cytochrome P450, mainly by CYP2C19 and the remainder by CYP3A4. It is a moderate CYP2C19 inhibitor and, because of its low affinity for CYP3A4, has no potential to inhibit the metabolism of CYP3A4 substrates (omeprazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.5 and 5.2). As examples of drugs whose exposure omeprazole may increase through CYP2C19, its SmPC names warfarin and other vitamin K antagonists, cilostazol, diazepam and phenytoin. Apixaban is not among them (AEMPS, section 4.5).

Symptoms

The documents describe no symptoms caused by this combination. Apixaban increases the risk of bleeding. The most common adverse reactions are haemorrhage, contusion, epistaxis and haematoma (apixaban SmPC, European Medicines Agency, EMA, sections 4.4 and 4.8). Severe hypomagnesaemia has been reported in people treated with proton pump inhibitors such as omeprazole for at least three months (omeprazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4).

Management

According to the documents, the combination is acceptable and no dose change of apixaban or omeprazole is needed. Neither document names the pair, reduced gastric acidity does not affect apixaban, and apixaban is not among the drugs whose metabolism omeprazole may slow (apixaban SmPC, European Medicines Agency, EMA, section 4.5; Losec SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Apixaban is used with caution in conditions with an increased risk of bleeding and is stopped if severe haemorrhage occurs (apixaban SmPC, EMA, section 4.4).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Apixaban

Other interactions with Omeprazole